The composition of our gut microbiome may influence addiction by triggering brain inflammation in regions of impulse control and increasing the severity of withdrawal symptoms.

An imbalance in gut microbiome flora can lead to a condition known as dysbiosis. This condition is typically characterized by a drop in microbiota diversity and an increase in harmful unicellular and acellular organisms, such as viruses, that can negatively impact the host's immune system and overall health. Genetics, infections, dietary choices, antibiotics, food additives, artificial sweeteners, and other lifestyle and environmental factors can cause dysbiosis.

The gut-microbiome connection may involve the enteric nervous system, a collection of hundreds of millions of neurons throughout the gut that transmit signals up the vagus nerve to the brain.

Certain unhealthy foods can promote gut bacterial growth and inflammation in the lining of the gut, potentially disrupting its lining—leading to a leaky gut that may allow pathogens to dribble out into the bloodstream, fueling further inflammation that can both cause disease flare-ups and set the stage for future disease development.

Alcohol doesn't just make you tipsy—it rewires your brain chemistry in real time. It slows your brain with GABA, spikes dopamine to make you feel unstoppable, and blocks glutamate so you can't form memories. That mix explains everything from slurred speech to blackouts … and brutal hangovers.

The gut microbiome is so influential to overall human health that some researchers consider it a separate organ. Its conditions, influenced by environmental and lifestyle factors such as medication and exercise, contribute to immunity, metabolism, inflammation, medical treatment efficacy, brain development and function, and the development of disorders and diseases, including asthma, depression, inflammatory bowel disease, and Alzheimer's.

Certain gut microbes in mice trigger dopamine release and drive motivation to exercise more. Scientists are investigating whether humans carry similar microbial patterns that influence our natural inclination towards movement, exploring how unseen microbial ecosystems may shape mammalian fitness behavior and reinforce innate reward pathways.

Researchers are investigating different strategies to determine if one day they could give people a combination of gut microbes to set them up for fewer allergies. In animal research, scientists have already prevented severe allergic responses in allergy-prone mice—supplying them with gut microbes from healthy, non-allergic human babies.

Alcohol is the world's most popular drug—a molecule that can calm or excite and bond communities or tear them apart. We trace alcohol's journey from ancient rituals to modern hangovers, uncover how it shaped civilizations, and dive into the neuroscience of how it affects your brain and body. With insights from leading experts, we ask: Given all that we know, why do humans continue to drink?

A helpful resource from the National Institute on Drug Abuse (part of the NIH). This article examines addiction treatment and recovery through the science behind several accepted methods. The guide draws helpful comparisons with other chronic disease treatments. In particular, it discusses the overlap between medications and therapeutic treatments, and the understanding that relapse doesn’t indicate treatment failure—only a need for continued or modified care.

The brain seems to experience a sharp increase in communication between areas that generally don't interact. New research suggests a thin, sheet-like gray matter structure tucked deep within the brain, between the insular cortex and striatum, may be the key to this change. The area is centrally located and home to many of the receptors that psychedelics target, potentially rewiring the brain and rewriting thought patterns.

Animal studies involving microdoses of psilocybin, the psychoactive component in magic mushrooms and ketamine, found it helped to alleviate anxiety and inflammation, an immune response that can cause damage when chronically active. Human studies are ongoing. In at least one double-blind study, where researchers and patients don't know who got a placebo versus the real thing, about half of the participants incorrectly guessed they had been given placebos.

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

When opioids enter the brain, they dock in receptors, blocking electrical pulses such as those that communicate pain. They also trigger the release of dopamine, a neurotransmitter tied to motivation and associated with stress relief.

Depressed brains can have certain characteristic changes, including an overactive amygdala, reduced hippocampus size, and changes to the thalamus and neuromodulating chemicals in the brain.

Treatment for depression has historically hinged on the theory that the condition was caused by underactive or abnormal neurotransmitters, specifically serotonin and norepinephrine. This four-minute video by Yale Medicine details how these neurotransmitters didn't explain the symptoms of depression but, two other neurotransmitters involved in regulating mood and emotion did. GABA and glutamate, some of the brain's most plentiful neurotransmitters, may possibly be the source of depressive symptoms.

A study published in early 2026 found a link between vitamin B1 and the successful movement of food through your GI tract, known as gut motility. The work incorporated genetic and survey data about poop frequency to identify genes associated with gut motility and then separately linked poop frequency data with how much vitamin B1 people ingested, theorizing that the vitamin supports the production of acetylcholine, a neurotransmitter that stimulates GI system contractions.

Instead of deleting genes, epigenetic editing modulates their activity. A new paper tests if it’s able to undo a genetic effect of early alcohol exposure.

Brain imaging shows that ayahuasca, MDMA, DMT, and psilocybin profoundly affect neural activity, giving rise to higher states of introspection and consciousness. This article details exactly how each of these drugs physically affects the brain and what that means for mental health treatment. Some of these drugs quiet the brain or trigger the release of neurochemicals associated with mood regulation and learning.

Recent DNA sequencing and molecular biology studies suggest that similarities in genes, neural circuitry and patterns of disease warrant further exploration to potentially better understand both conditions and how to treat them.

In the lab, mice dosed with probiotics prior to inducing exertional heatstroke, had better cognitive outcomes. This evidence underscores the links between the gut microbiome and the brain, at least in rodents.

Researchers analyzed the DNA of more than 53,000 people with OCD and identified 30 areas in the genome linked to the disease, containing 249 genes of interest. Of those, several were linked to other brain disorders, paving the way for genetic treatments of various mental illnesses.

Burnout isn't just a feeling—it physically affects the brain. Prolonged stress impairs regions of the brain responsible for decision-making, emotional control, memory, and more. It can also lead to chemical imbalances, like reduced dopamine and norepinephrine levels, that worsen these effects.

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.